Albert Labs CEO Dr Michael Raymont joined Proactive’s Katie Pilbeam to talk about their plans to commence trading on the CSE under the ticker "ABRT" early in the new year.
The firm is working on making psychedelic-based medicines for patients more accessible, siting an urgent and unmet need for such treatments.
This is in coordination with a previously announced transaction, with news of the company’s pending reverse listing into ME Resource Corp (CSE:MEC) (OTC:MEEXF).